INT47741

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 1994
Last Reported 2010
Negated 0
Speculated 2
Reported most in Abstract
Documents 43
Total Number 45
Disease Relevance 5.72
Pain Relevance 23.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Flvcr2) transmembrane transport (Flvcr2)
Anatomy Link Frequency
striatum 3
spinal nerve 1
tail 1
brain 1
neural 1
Flvcr2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Glutamate 464 100.00 Very High Very High Very High
Dopamine 120 100.00 Very High Very High Very High
Serotonin 55 100.00 Very High Very High Very High
cocaine 35 100.00 Very High Very High Very High
withdrawal 26 100.00 Very High Very High Very High
noradrenaline 17 100.00 Very High Very High Very High
Endocannabinoid 16 100.00 Very High Very High Very High
antidepressant 108 99.92 Very High Very High Very High
Morphine 30 99.84 Very High Very High Very High
Enkephalin 10 99.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Neuropathic Pain 36 99.42 Very High Very High Very High
Nervous System Injury 13 99.00 Very High Very High Very High
Hypersensitivity 11 98.88 Very High Very High Very High
Nociception 46 98.12 Very High Very High Very High
Pain 97 97.96 Very High Very High Very High
Sprains And Strains 2 97.88 Very High Very High Very High
Respiratory Tract Infection 3 97.84 Very High Very High Very High
Hypertension 3 97.56 Very High Very High Very High
Injury 30 96.04 Very High Very High Very High
Morphine Dependence 10 95.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This enhancement was inhibited by a specific glutamate transporter inhibitor.
Negative_regulation (inhibitor) of transporter associated with glutamate
1) Confidence 0.51 Published 2001 Journal Neuroreport Section Abstract Doc Link 11303749 Disease Relevance 0 Pain Relevance 0.76
Methylphenidate is a psychostimulant which inhibits the dopamine transporter and produces dopamine overflow in the striatum, similar to the effects of cocaine.
Negative_regulation (inhibits) of transporter in striatum associated with dopamine and cocaine
2) Confidence 0.43 Published 2003 Journal Eur. J. Neurosci. Section Abstract Doc Link 14511337 Disease Relevance 0 Pain Relevance 0.37
The present results indicate that triadimefon acts in vivo as a DA transporter inhibitor and could also act on the serotoninergic system.
Negative_regulation (inhibitor) of transporter associated with dopamine
3) Confidence 0.43 Published 2006 Journal Toxicology Section Abstract Doc Link 16246478 Disease Relevance 0 Pain Relevance 0.45
Fluoxetine, as a serotonin re-uptake inhibitor augments serotonin concentration within the synapse by inhibiting the serotonin transporter.
Negative_regulation (inhibiting) of transporter in synapse associated with serotonin and fluoxetine
4) Confidence 0.41 Published 2007 Journal Neurochem. Res. Section Abstract Doc Link 17486443 Disease Relevance 0.10 Pain Relevance 0.64
In this study, we examined the effect of intracerebroventricular (i.c.v.) administration of a potent glutamate transporter inhibitor, DL-threo-beta-benzyloxyaspartate (DL-TBOA), on acute morphine-induced antinociception, expression of somatic and negative affective components of morphine withdrawal, and acquisition of morphine-induced conditioned place preference in rats.
Negative_regulation (inhibitor) of transporter associated with antinociception, glutamate, withdrawal, intracerebroventricular and morphine
5) Confidence 0.38 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 14757142 Disease Relevance 0.17 Pain Relevance 1.15
EXPERIMENTAL APPROACH: In this report, we present the in vitro pharmacological and in vivo pharmacokinetic and pharmacological properties of the novel, orally available and CNS penetrant inhibitor of the noradrenaline transporter (NET), WAY-318068 (1-[(1S,2R)-1-(3,5-difluorophenyl)-2-hydroxy-3-(methylamino)propyl]-7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one).
Negative_regulation (inhibitor) of transporter
6) Confidence 0.35 Published 2010 Journal Br. J. Pharmacol. Section Body Doc Link 20590604 Disease Relevance 0 Pain Relevance 0
KEY RESULTS: WAY-318068 is a potent and effective inhibitor of the NET with a K(i) of 8.7 nM in a binding assay, and an IC(50) of 6.8 nM in an assay of transporter function, without significant binding to the dopamine transporter.
Negative_regulation (inhibitor) of transporter
7) Confidence 0.35 Published 2010 Journal Br. J. Pharmacol. Section Body Doc Link 20590604 Disease Relevance 0 Pain Relevance 0
Fluoxetine and citalopram (10(-6) M and 10(-5) M), inhibitors of 5-HT transporter, did not affect 5-HT-IR in the IL fibers, unless they were used in concentrations high enough (10(-4) M and 10(-3) M) to block unspecifically a number of monoamine transporters.
Negative_regulation (inhibitors) of transporter associated with monoamine and fluoxetine
8) Confidence 0.35 Published 1994 Journal Neurosci. Res. Section Abstract Doc Link 7724065 Disease Relevance 0 Pain Relevance 0.66
The same applied for desipramine (10(-5)-10(-7) M), an inhibitor of the noradrenaline transporter.
Negative_regulation (inhibitor) of transporter associated with desipramine and noradrenaline
9) Confidence 0.35 Published 1994 Journal Neurosci. Res. Section Abstract Doc Link 7724065 Disease Relevance 0 Pain Relevance 0.78
The degree of receptor downregulation, as well as transporter upregulation, became less evident after more prolonged drug administration.
Negative_regulation (downregulation) of transporter
10) Confidence 0.32 Published 2000 Journal Headache Section Body Doc Link 10849027 Disease Relevance 0 Pain Relevance 0
These results indicate that IBU treatment alters sodium-dependent sulfate cotransport by a downregulation of mRNA and protein of NaSi-1 transporter in BBM.
Negative_regulation (downregulation) of transporter in BBM
11) Confidence 0.32 Published 1998 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 9864297 Disease Relevance 0 Pain Relevance 0
Riluzole's pronounced suppressive effects on spinal EAA levels is attributed to its established role as a glutamate release inhibitor and an enhancer of glutamate transporter activity.
Negative_regulation (inhibitor) of transporter in spinal associated with glutamate
12) Confidence 0.30 Published 2007 Journal J. Neurochem. Section Abstract Doc Link 17241130 Disease Relevance 0.32 Pain Relevance 1.19
The mu-receptor may manifest, as do other neural markers (e.g., dopamine transporter, dopamine efflux), a biphasic temporal pattern with upregulation during early phases of cocaine withdrawal but a downregulation at later times.
Negative_regulation (downregulation) of transporter in neural associated with dopamine, withdrawal and cocaine
13) Confidence 0.29 Published 2000 Journal Synapse Section Abstract Doc Link 10891866 Disease Relevance 0 Pain Relevance 0.80
These experiments confirm and extend previous reports concerning the ability of nefazodone to inhibit the 5-HT transporter in vivo.
Negative_regulation (inhibit) of transporter
14) Confidence 0.28 Published 1995 Journal Life Sci. Section Abstract Doc Link 7475971 Disease Relevance 0 Pain Relevance 0.24
To date, UCM707, N-(3-furylmethyl)eicosa-5,8,11,14-tetraenamide, has the highest potency and selectivity in vitro as inhibitor of the endocannabinoid transporter, which might make this compound useful in potentiating endocannabinoid transmission, with minimal side-effects, in the treatment of several disorders.
Negative_regulation (inhibitor) of transporter associated with endocannabinoid and potency
15) Confidence 0.26 Published 2002 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12163112 Disease Relevance 0 Pain Relevance 0.37
In summary, UCM707, as suggested by its in vitro properties, seems also to behave in vivo as a selective and potent inhibitor of the endocannabinoid transporter, showing negligible direct effects on the receptors for endocannabinoids but potentiating the action of these endogenous compounds.
Negative_regulation (inhibitor) of transporter associated with endocannabinoid
16) Confidence 0.26 Published 2002 Journal Eur. J. Pharmacol. Section Abstract Doc Link 12163112 Disease Relevance 0 Pain Relevance 0.43
Whether glycine transporter inhibitors have the capability to gain clinical relevance as analgesic compounds on the long run has to be elucidated in further investigations.
Spec (Whether) Negative_regulation (inhibitors) of transporter associated with analgesic
17) Confidence 0.22 Published 2008 Journal Neurosci. Lett. Section Abstract Doc Link 18793697 Disease Relevance 0.87 Pain Relevance 0.64
An elevation of extracellular glutamate concentration by a glutamate transporter inhibitor, TBOA, suppressed the evoked EPSCs.
Negative_regulation (inhibitor) of transporter associated with glutamate
18) Confidence 0.21 Published 2005 Journal J. Neurosci. Res. Section Abstract Doc Link 16273546 Disease Relevance 0.13 Pain Relevance 0.64
These results compared to data in the literature suggest that the first increase in extracellular DA resulted mainly from a release of cytosolic DA by reversal of the DA transporter, while the second was mainly due to a release of vesicular DA by exocytosis.
Negative_regulation (reversal) of transporter associated with dopamine
19) Confidence 0.21 Published 1999 Journal Neuroreport Section Abstract Doc Link 10501541 Disease Relevance 0.07 Pain Relevance 0.60
In addition, maternal separation produces a reduction in glial excitatory amino acid transporter (EAAT)-1 with no change in EAAT-2 or gamma-amino butyric acid transporters.
Negative_regulation (reduction) of transporter
20) Confidence 0.19 Published 2010 Journal Gastroenterology Section Body Doc Link 20226190 Disease Relevance 0.11 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox